SYMBIOTEC

Order Win: Symbiotec's wholly owned subsidiary Knovea Pharmaceutical won a strategic commercialization agreement from a leading global pharmaceutical company Order Value: Not disclosed due to confidentiality (addresses a U.S. market estimated at approximately US$288 million) Completion Timeline: Long-term agreement with milestone payments through development, regulatory approval, and commercial launch, alongside profit-sharing from launch onwards

Order Win: Symbiotec Pharmalab Limited's subsidiary Knovea Pharmaceutical entered into a strategic commercialization agreement with a leading global pharmaceutical company Order Value: Addresses a U.S. market estimated at approximately US$288 million Completion Timeline: Long-term agreement with milestone payments through development, regulatory approval, and commercial launch, alongside profit-sharing from launch onwards.

- Symbiotec Pharmalab Limited received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility located in Pithampur (SEZ), Madhya Pradesh. - The inspection classification is Voluntary Action Indicated (VAI). - The inspection was conducted from August 10, 2026, to August 14, 2026.